List of Excipients in Branded Drug DEFERASIROX

Generic Drugs Containing DEFERASIROX

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	deferasirox	0093-3517	CROSPOVIDONE
Teva Pharmaceuticals USA Inc	deferasirox	0093-3517	FD&C BLUE NO. 2--ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	deferasirox	0093-3517	FD&C RED NO. 40
Teva Pharmaceuticals USA Inc	deferasirox	0093-3517	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	deferasirox	0093-3517	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in DEFERASIROX?

# Of NDCs	Excipient
3	CASTOR OIL
29	CELLULOSE, MICROCRYSTALLINE
11	CROSCARMELLOSE SODIUM
32	CROSPOVIDONE
7	FD&C BLUE NO. 2

Deferasirox Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Deferasirox is an oral iron chelator marketed in multiple dosage-form designs, including dispersible tablets, film-coated tablets, and oral granules. The commercial opportunity has shifted from basic generic substitution to differentiated products that improve taste, dispersion, dose flexibility, gastrointestinal tolerability, storage stability, and pediatric administration.

The strongest excipient opportunities are in oral granules, taste-masked pediatric formulations, rapidly dispersible tablets, and lower-volume administration systems. Deferasirox has limited remaining U.S. exclusivity protection, so formulation differentiation and regulatory execution are more important than blocking generic entry through the core active ingredient.

What is the FDA regulatory status of deferasirox?

FDA-approved deferasirox products include Exjade dispersible tablets, Jadenu film-coated tablets, Jadenu oral granules, and generic versions of these dosage forms.

Product or dosage form	Active ingredient	Administration	Commercial status
Exjade	Deferasirox	Dispersed in liquid before administration	Originator product; generic competition established
Jadenu tablets	Deferasirox	Swallowed directly, generally with or without a light meal	Originator product; generic competition established
Jadenu granules	Deferasirox	Sprinkled on soft food	Originator product; dosage-form differentiation
Generic deferasirox tablets for oral suspension	Deferasirox	Dispersed in liquid	FDA-approved generic category
Generic deferasirox film-coated tablets	Deferasirox	Swallowed directly	FDA-approved generic category
Generic deferasirox oral granules	Deferasirox	Administered with soft food	Formulation-specific generic opportunity

Exjade received FDA approval in 2005. Jadenu tablets and granules were approved in 2015 as successor dosage forms intended to improve administration and reduce the burden associated with dispersing Exjade tablets before dosing.[1,2]

Deferasirox is used for chronic iron overload associated with transfusion-dependent anemias and non-transfusion-dependent thalassemia. Dosing is weight-based, which creates a recurring need for strengths, dose combinations, and pediatric-friendly administration options.

Which excipients are used in deferasirox products?

The excipient system varies by dosage form. The main formulation functions are wetting, dispersion, tablet binding, disintegration, coating, taste management, and physical stabilization.

Exjade dispersible tablets

Exjade is designed to disperse in liquid before administration. Its excipient strategy must support rapid breakup and uniform distribution of the active ingredient without producing excessive foaming, sedimentation, or unpleasant mouthfeel.

The product label identifies conventional solid-dose excipients, including microcrystalline cellulose, crospovidone, povidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.[1] The precise formulation role of each excipient is commercially relevant:

• Microcrystalline cellulose provides tablet structure and contributes to disintegration.
• Crospovidone accelerates tablet breakup.
• Povidone acts as a binder.
• Sodium lauryl sulfate improves wetting of the poorly water-soluble active ingredient.
• Colloidal silicon dioxide improves powder flow and may reduce cohesion.
• Magnesium stearate provides lubrication but can slow wetting if overused.

Exjade’s excipient profile creates opportunities for products that disperse faster, leave less residue in the dosing vessel, and reduce the need for vigorous mixing.

Jadenu film-coated tablets

Jadenu tablets use a direct-swallow design rather than the dispersible-tablet procedure required for Exjade. This reduces administration time and eliminates the need to prepare a liquid suspension.

The formulation requires adequate mechanical strength, low friability, rapid gastrointestinal disintegration, and acceptable swallowability. Film coating can reduce powdery mouthfeel and improve handling. It also creates a platform for coating optimization, including opacity, moisture protection, and reduced surface adhesion.

The major excipient risks are excessive hardness, delayed disintegration, and increased tablet size. These risks are important because deferasirox doses can be high on a milligram-per-kilogram basis, particularly in patients with substantial iron burden.

Jadenu oral granules

Oral granules are the most commercially attractive dosage form for excipient innovation. The granules can be sprinkled onto soft food, which supports pediatric use and patients who cannot swallow tablets.

The principal formulation requirements are:

1. Narrow particle-size distribution.
2. Low dust generation.
3. Uniform drug content across dose portions.
4. Minimal taste release before swallowing.
5. Stability under humidity exposure.
6. Reliable transfer from the sachet or container.
7. Compatibility with soft foods.

Granule technology permits greater control over taste masking than a conventional tablet. Coated multiparticulates, lipid barriers, polymer films, ion-exchange systems, and functional carbohydrate matrices are possible approaches. Each approach must preserve dose uniformity and avoid delaying absorption beyond the reference product’s clinically relevant profile.

What excipient properties matter most for deferasirox?

Solubility and wetting

Deferasirox is a poorly water-soluble compound. Wetting agents and disintegrants can improve dispersion, but higher surfactant levels may increase gastrointestinal adverse effects or alter the dissolution profile.

Commercial formulations should balance:

• Initial wetting speed.
• Dissolution in physiologic pH conditions.
• Low foaming during preparation.
• Limited surfactant exposure.
• Reproducible performance across storage conditions.

A formulation that disperses quickly in water but precipitates rapidly or adheres to the dosing vessel may have poor real-world performance.

Metal-ion compatibility

Deferasirox is a metal chelator. Excipients and processing equipment should therefore be assessed for trace-metal contamination and potential interaction with the active ingredient.

Risk controls include:

• Low-iron excipient specifications.
• Control of aluminum, calcium, magnesium, and other metallic impurities.
• Evaluation of excipient lots for metal-ion variability.
• Use of compatible manufacturing contact surfaces.
• Stability testing under elevated humidity and temperature.
• Monitoring for assay loss, degradation, and dissolution changes.

Magnesium-containing lubricants are not automatically unsuitable, but their concentration, distribution, and effect on dissolution require product-specific assessment. The same principle applies to mineral-containing pigments, inorganic glidants, and certain processing aids.

Taste and mouthfeel

Deferasirox has a bitter taste. Taste masking is commercially important because treatment is chronic and adherence can decline when administration is unpleasant.

Useful technologies include:

• Polymer-coated particles.
• Lipid-coated granules.
• Ion-exchange resin complexes.
• Cyclodextrin-based systems.
• Lipid-based taste barriers.
• Effervescent or rapidly dispersible systems that reduce residence time in the mouth.
• Flavor systems compatible with the target age group.

Taste masking should be evaluated with human sensory testing or validated electronic-tongue methods, followed by clinical confirmation where needed. A coating that prevents bitterness in a short bench test may fail after storage, chewing, or mixing with acidic food.

Dose flexibility

Weight-based dosing favors formulations that allow incremental dose adjustment. Granules and multiple tablet strengths can support this need more effectively than a single high-strength tablet.

A commercial product can differentiate through:

• Smaller tablet strengths.
• Scored tablets where technically and regulatorily appropriate.
• Unit-dose granule sachets.
• Multi-strength packs.
• Dose-combination packaging.
• Ready-to-use sprinkle formats.
• Child-resistant packaging with easier caregiver handling.

What formulations are protected by deferasirox patents?

The original deferasirox patent estate covered the active compound and related iron-chelating compositions. Later intellectual-property activity focused on pharmaceutical compositions, dispersible tablets, film-coated tablets, granules, dosing regimens, and manufacturing processes.

The current U.S. competitive position is defined by approved generic products and the expiration of the principal originator exclusivity period. FDA Orange Book records should be used to identify any listed patents or regulatory exclusivities associated with a specific reference product and dosage form.[3]

IP category	Commercial relevance
Core deferasirox compound	Limited barrier because the main U.S. exclusivity period has ended
Dispersible-tablet composition	May affect legacy Exjade-style products, but generic pathways are established
Film-coated tablet formulation	Relevant to Jadenu-style products and bioequivalence strategy
Oral granule formulation	Potentially valuable where taste masking, particle coating, or administration method is differentiated
Method-of-use claims	May cover patient populations or dosing approaches, subject to enforceability and listing status
Manufacturing claims	Can create supply-chain barriers if they produce a material quality or cost advantage
Packaging and device claims	Usually weaker as standalone barriers but can support product differentiation

Exact patent scope must be evaluated claim by claim. A formulation patent is commercially stronger when it covers a necessary performance attribute, such as a defined dissolution profile, stable coated granule architecture, or a narrowly specified excipient ratio. Broad claims directed only to routine excipient substitution are more vulnerable to invalidity and design-around attacks.

When does deferasirox lose exclusivity?

The principal U.S. market exclusivity associated with deferasirox has already passed, and FDA-approved generic competition is present. Deferasirox therefore operates in a post-exclusivity market in which the relevant question is not whether generic entry is possible, but how many differentiated products can obtain approval and secure preferred distribution.

Exclusivity category	Current commercial implication
New chemical entity exclusivity	Expired
Core compound patent protection	No longer a reliable barrier to U.S. generic entry
Pediatric exclusivity	Historical period; no longer prevents current generic competition
Formulation-specific protection	Must be checked against the exact dosage form and claim scope
Regulatory exclusivity for new products	May apply only to a newly approved, qualifying innovation
Orphan-drug considerations	Disease-specific benefits do not automatically block all deferasirox products

Generic manufacturers can pursue abbreviated new drug applications for relevant dosage forms by demonstrating pharmaceutical equivalence and bioequivalence. A novel excipient system does not eliminate the need to match the reference product’s critical quality and pharmacokinetic characteristics.

What generic entry risks exist for deferasirox?

Generic entry risk is high for conventional tablets and established dispersible tablets. The strongest remaining commercial barriers are operational rather than molecule-based.

High-risk segments

• Standard film-coated tablets.
• Conventional tablets for oral suspension.
• Products using commonly available excipients.
• Large-volume hospital or specialty-pharmacy channels.
• Products competing mainly on price.

Moderate-risk segments

• Oral granules with basic taste masking.
• Products with multiple strengths but no adherence advantage.
• Formulations requiring complex manufacturing but offering limited clinical benefit.

Lower-risk segments

• Pediatric products with demonstrated taste and adherence advantages.
• Stable granules with precise dose partitioning.
• Low-dust unit-dose products.
• Products that reduce preparation time and dosing errors.
• Formulations designed for patients with swallowing difficulty or gastrointestinal intolerance.

The regulatory burden increases when a formulation changes the release mechanism, absorption profile, or administration conditions. A product that is materially different from the reference dosage form may require a 505(b)(2) application rather than an ANDA, depending on the formulation and proposed labeling.

How strong is the deferasirox patent estate?

The estate is moderate for legacy formulation concepts and weak as a broad barrier to U.S. generic entry. Its residual value is highest in narrow claims directed to specific dosage forms, excipient ratios, coated particles, granulation processes, or administration methods.

Factors supporting patent strength

• Defined particle or granule architecture.
• Demonstrated taste masking.
• Unexpected dissolution or stability results.
• Narrow but technically necessary excipient combinations.
• Process controls that materially affect product quality.
• Claims supported by comparative data against Exjade or Jadenu.

Factors weakening patent strength

• Routine substitution of binders or disintegrants.
• Broad claims covering ordinary tablet excipients.
• Lack of comparative performance data.
• Easy substitution with another surfactant or coating polymer.
• Claims that read on predictable formulation optimization.
• Failure to distinguish the product from prior deferasirox dosage forms.

A new product should rely on a coordinated portfolio covering composition, process, use, packaging, and possibly device features. A single formulation patent is less durable when competing products can use a different excipient family to achieve the same clinical and manufacturing result.

Which companies are challenging deferasirox exclusivity?

Generic competition includes companies that have filed or marketed FDA-approved deferasirox products in the tablet, dispersible-tablet, film-coated-tablet, or granule categories. The FDA Orange Book and FDA product databases identify approved applicants and reference-product relationships.[3,4]

The competitive field typically includes:

• Large generic manufacturers with established ANDA infrastructure.
• Specialty generic companies focused on complex oral solids.
• Contract development and manufacturing organizations with granulation and coating capabilities.
• Regional suppliers serving hematology and transfusion centers.
• Companies pursuing pediatric or adherence-focused formulations.

Paragraph IV risk is primarily relevant to any remaining listed formulation or method-of-use patent. For a post-exclusivity drug with established generics, a Paragraph IV filing may accelerate entry, trigger litigation, or support an at-risk launch. Settlement agreements, if any, must be reviewed in the relevant district-court docket and FDA listing records. They should not be inferred from the existence of a generic approval alone.

What commercial opportunities exist in deferasirox excipients?

Pediatric taste-masked granules

This is the clearest opportunity. A granule product that reduces bitterness, dust, dosing errors, and preparation time can compete on adherence rather than price alone.

The most promising excipient platforms are polymer-coated multiparticulates and lipid-polymer hybrid coatings. The product should maintain rapid release after swallowing and demonstrate acceptable compatibility with common soft foods.

Low-volume dispersible tablets

A reformulated dispersible tablet could reduce the volume of liquid required for administration. This may improve caregiver compliance and reduce residual drug left in cups or syringes.

The commercial target is a tablet that:

• Disperses rapidly.
• Produces minimal sediment.
• Requires limited stirring.
• Leaves low residue.
• Has controlled foaming.
• Maintains dose uniformity after preparation.

Sprinkle formulations

Sprinkle products can address patients unable to swallow tablets. The formulation should avoid excessive grittiness, bitterness, and adherence to food or utensils.

A patentable product may combine a defined granule size range with a taste-masking coating and a specific administration method.

Gastrointestinal-tolerability platforms

Deferasirox can produce gastrointestinal adverse reactions. Excipients that reduce local concentration spikes or improve dispersion may support a differentiated product, but any tolerability claim requires clinical evidence.

Potential approaches include:

• More uniform particle distribution.
• Controlled wetting.
• Reduced surfactant loading.
• Modified food-effect behavior.
• Protective multiparticulate coatings.

Supply-chain and packaging improvements

Unit-dose sachets, moisture-barrier films, desiccant systems, and high-integrity closures can protect hygroscopic or coated granules. Packaging patents are generally secondary, but they can support market access and reduce product loss.

How does deferasirox compare with competing iron chelators?

Drug	Main route	Formulation opportunity	Commercial implication
Deferasirox	Oral, once daily in many regimens	Granules, film-coated tablets, taste masking	Strong adherence and pediatric opportunity
Deferoxamine	Parenteral	Infusion systems and injectable excipients	Administration burden limits convenience
Deferiprone	Oral	Tablets and oral solution; taste and dosing flexibility	Competes in oral chelation, with different safety and dosing considerations

Deferasirox has a formulation advantage because it is orally administered and has established solid-dose platforms. The main weakness is chronic tolerability and the need for accurate weight-based dosing. Excipients that improve administration without changing exposure materially are more commercially attractive than aggressive modified-release concepts.

What FDA and CMC issues affect a new deferasirox excipient product?

A new product must address more than dissolution. FDA review is likely to focus on:

• Comparative dissolution across relevant pH conditions.
• Particle-size distribution.
• Content uniformity.
• Dose recovery from the administration vessel or food.
• Taste-masking performance.
• Stability under humidity and temperature stress.
• Trace-metal impurities.
• Excipient compatibility.
• Bioequivalence or clinical bridging.
• Food-effect behavior.
• Packaging integrity.
• Extractables and leachables where applicable.

For pediatric products, FDA may also examine administration acceptability, dosing error risk, swallowability, and caregiver usability. A formulation that reduces the number of preparation steps can provide a practical advantage even without a new pharmacologic claim.

What is the revenue exposure for deferasirox formulation products?

Originator revenue exposure has declined because of generic substitution and the availability of multiple dosage forms. Public company filings generally do not provide a standalone, current revenue line for every deferasirox formulation. Commercial value is therefore concentrated in market share, channel access, manufacturing cost, and differentiated dosage-form positioning rather than in broad molecule-level exclusivity.

The most defensible revenue opportunities are:

1. Premium pediatric granules.
2. Specialty-pharmacy products with adherence support.
3. Lower-cost, high-throughput generic film-coated tablets.
4. Contract-manufactured granules for regional markets.
5. Products with strong supply reliability in hematology channels.

Key Takeaways

• Deferasirox is a post-exclusivity oral iron chelator with established generic competition.
• Excipients are most valuable when they improve taste, dispersion, dose flexibility, tolerability, or storage stability.
• Oral granules are the strongest platform for commercial and patent differentiation.
• Metal-ion control is a critical CMC issue because deferasirox chelates metals.
• Conventional film-coated tablets face high generic-entry risk and limited pricing power.
• Taste-masked pediatric products can compete on adherence and administration convenience.
• Residual patent value is concentrated in narrow formulation, granule, process, and administration claims.
• FDA approval strategy depends on whether the product remains pharmaceutically equivalent to an existing reference product or requires a 505(b)(2) pathway.
• Packaging, dose partitioning, and preparation-time reductions can support commercial differentiation but rarely provide a standalone market barrier.

FAQs

Can deferasirox be formulated with standard tablet excipients?

Yes. Standard binders, disintegrants, lubricants, glidants, and surfactants can be used, but the formulation must control wetting, dissolution, trace-metal contamination, and gastrointestinal tolerability.

Is a taste-masked deferasirox product likely to be patentable?

It may be patentable if the product has a defined coating or excipient architecture supported by unexpected taste, stability, dissolution, or adherence results. Routine flavor addition alone is unlikely to provide strong protection.

Are deferasirox oral granules suitable for pediatric commercialization?

Yes. Oral granules can support weight-based dosing and administration with soft food. The key development issues are taste, dose uniformity, particle size, dust control, food compatibility, and caregiver usability.

Can an excipient change support a 505(b)(2) application for deferasirox?

Potentially. A material formulation or administration change may support a 505(b)(2) pathway when the product cannot rely fully on the ANDA route. The pathway depends on the nature of the difference and the evidence needed to bridge to the reference product.

What is the most attractive contract-manufacturing opportunity for deferasirox?

The strongest opportunity is specialty manufacturing of coated oral granules or multiparticulates with low-dust handling, high dose uniformity, moisture protection, and validated taste masking.

References

1. U.S. Food and Drug Administration. (2020). Exjade (deferasirox) tablets for oral suspension: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2020). Jadenu (deferasirox) tablets and granules: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

5. International Council for Harmonisation. (2009). Pharmaceutical development Q8(R2). ICH.

6. International Council for Harmonisation. (2023). Guideline for elemental impurities Q3D(R2). ICH.